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In this work, an anti-loxoscelic serum was produced by immunizing horses with a recombinant der-
monecrotic protein from Loxosceles intermedia (rLiD1). Anti-rLiD1 antibodies were able to recognize
different species of Loxosceles venoms by Western Blot and ELISA. The efﬁcacy of anti-rLiD1 serum
against the toxic effects of Loxosceles laeta (Peru) venom was tested, showing that anti-rLiD1 serum can
neutralize those effects. This study conﬁrms that recombinant proteins can be good candidates to replace
crude venoms for antivenom production.
© 2014 Elsevier Ltd. All rights reserved.Loxosceles spiders are distributed worldwide, found in several
continents. These spiders represent a group of medical importance
in North America, Latin America, Europe, Middle East and other
parts of Asia, Africa and Australia (Futrell, 1992; da Silva et al.,
2004). Loxosceles venoms are responsible for a syndrome called
loxoscelism, which presents itself in two forms: the cutaneous
form, which causes pain and erythema that can develop into a
necrotic ulcer; and the systemic loxoscelism, which is characterized
by intravascular hemolysis and occasional renal failure (da Silva
et al., 2004; Ministerio da Saúde, 2011).
Loxosceles venoms present a complex mixture of toxic protein
components such as hyaluronidases, metalloproteases, peptides
and sphingomyelinases D. The sphingomyelinase D family mem-
bers are also called dermonecrotic toxins and are the main
responsible for toxic effects and pathogenesis of Loxosceles en-
venomation (Tambourgi et al., 1998).ca e Imunologia, Instituto de
ais, CP: 486. CEP: 30.161-970,
lortegui).The Public Health Organizations recommend the application of
commercial antivenoms produced by hyperimmunization of horses
with Loxosceles venoms as treatment for spiders bites (Pauli et al.,
2009). The production of anti-loxoscelic antivenom is limited, due
to the difﬁculty in obtaining the necessary amounts of venom, since
these spiders have small venom glands with restricted production.
As an alternative for the utilization of crude venom, recombinant
dermonecrotic proteins or their epitopes has been used as immu-
nogens for therapeutic serum development or vaccination ap-
proaches (Olvera et al., 2006; de Almeida et al., 2008; Dias-Lopes
et al., 2010; de Moura et al., 2011; Mendes et al., 2013; Figueiredo
et al., 2014).
In the present study, we compared the neutralization efﬁcacy of
an anti-loxoscelic serum produced by immunization of horses with
a recombinant dermonecrotic protein (rLiD1) from Brazilian Lox-
osceles intermedia spider venom, produced previously
(Kalapothakis et al., 2002; Felicori et al., 2006) and standard anti-
venom used for loxoscelism therapy in Peru, developed against the
toxic effects of venom from Loxosceles laeta (Peru) spiders.
The venoms used throughout this study were collected from
dissected venom glands of mature spiders, according to da Silveira
C.G. Duarte et al. / Toxicon 93 (2015) 37e4038et al. (2002). L. laeta (Peru) were collected in the region of Ca~nete
(Lima, Peru) and maintained in the herpetarium INS in Lima, Peru.
Brazilian L. intermedia, L. gaucho and L. laeta (Brazil) spiders were
collected in the region of Curitiba, PR, Brazil and maintained at the
Centro de Produç~ao e Pesquisa de Imunobiologicos (CPPI) of the
State of Parana, Brazil. The venom protein concentration was
determined by the method of Bradford (1976). The minimum
necrotizing dose (MND) (lowest venom concentration that induces
a necrotic area of 1 cm2) used throughout this study was 6 mg.
rLiD1 was obtained as described by Felicori et al. (2006) and
used to immunize adult male horses. After collection of pre-
immune serum, the animals received an initial subcutaneous in-
jection of 200 mg of rLiD1 in complete Freund's adjuvant (day 1). SixFig. 1. Immunoreactivity characterization of anti-rLiD1 horse serum. (A) ELISA reactivity ag
Plates were coated with 1 mg of recombinant protein or venoms per well and reactivity teste
cross-reactivity was observed for all venoms. (B) SDS-PAGE 12.5% of Loxosceles venoms and
intermedia (Li), L. gaucho (Lg), L. laeta Brazil (Llb) and L. laeta Peru (Llp) and 10 mg of rLiD1 wer
and tested against anti-rLiD1 horse serum (1:500). An intense reaction with bands in the ra
sphingomyelinase D family, responsible for the toxic effects of Loxosceles venoms.booster injections were made subcutaneously 30, 60, 90, 120, 150
and 180 days later, with the same dose in incomplete Freund's
adjuvant. Blood samples were withdrawn one week after the last
injection.
Indirect ELISA and immunobloting assays were performed for
immunological characterization of anti-rLiD1 horse sera (Fig. 1),
according to Guimar~aes et al., 2013. For ELISA, plates were coated
with 100 ml of a 10 mg/ml solution of either rLiD1, L. intermedia, L.
gaucho, L. laeta (Brazil) and L. laeta (Peru). Sera from pre-immune
and immune horse were added in serial dilutions. Triplicate read-
ings were taken for all samples and means were calculated. Anti-
rLiD1 serum showed high reactivity against rLiD1, showing that
the immunization protocol was efﬁcient. An important cross-ainst rLiD1, L. intermedia, L. gaucho, L. laeta (Brazil) and L. laeta (Peru) spider venoms.
d against anti-rLiD1 serum using serial dilution from 1:100 to 1:12,800. A considerable
western blotting with anti-rLiD1 horse serum. Twenty mg of each Loxosceles venom L.
e analyzed. After analysis by SDS-PAGE, the gel was blotted in nitrocellulose membrane
nge of 34e26 kDa was observed. This molecular mass corresponds to proteins from the
Table 1
Neutralization of lethal activity. Groups of four mice received a subcutaneous doses
of 2.5 LD50 of L. intermedia or L. laeta (Peru) venoms (10 and 12.5 mg/20 g of mice,
respectively), pre-incubated with 100 ml of anti-rLiD1, anti-loxoscelic or pre-
immune sera. The venom was incubated only with PBS as a control. Forty-eight
hours after the injections, the deaths were recorded and the number of survivors
counted.
Surviving/Challenged (%)
L. intermedia L. laeta (Peru)
PBS 1/4 (25%) 0/4 (0%)
Pre-immune 1/4 (25%) 1/4 (25%)
Anti-rLiD1 4/4 (100%) 3/4 (75%)
Anti-L. laeta (Peru) 4/4 (100%) 4/4 (100%)
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detected, indicating that these antibodies could have venom
neutralization potential (Fig. 1A).
To access whether anti-rLiD1 antibodies could bind to venom's
sphingomyelinases D, immunoblotting was performed.
L. intermedia. L. gaucho, L. laeta (Brazil), L. laeta (Peru) venoms
(20 mg) and rLiD1 (10 mg) were ran on 12.5% SDS-PAGE (Laemmli,
1970). Gels were blotted onto nitrocellulose membranes (Towbin
et al., 1979). After transfer, the membrane was incubated with
anti-rLiD1 horse serum (1:500) for 1 h. Anti-rLiD1 serum was able
to recognize the analyzed venoms and rLiD1 (Fig. 1B). As expected,
there was a strong reactivity with components ranging from 26 to
34 kDa, which is the typical molecular mass of the sphingomyeli-
nases D family (Silvestre et al., 2005), the major component from
Loxosceles venoms and responsible from the main effects of these
spiders venom (da Silva et al., 2004). Machado et al. (2005), re-
ported several isoforms of dermonecrotic toxins in the venoms of
L. laeta, L. gaucho and L. intermedia Brazilian spiders, and Guimar~aes
et al. (2013) also shown that remarkable differences were detected
within this molecular weight range between Brazilian and Peruvian
populations of L. laeta venoms, explaining why different bands
were recognized in Western Blotting.
Since antibodies capable of binding to sphingomyelinases D
were detected in the anti-rLiD1 serum, neutralization assays were
performed. To evaluate the dermonecrotic, hemorrhagic and
oedematogenic neutralization, adult female New Zealand rabbits
(2e2.5 kg) weremaintained at the Centro de Bioterismo, ICB-UFMG
(Belo Horizonte, MG, Brazil). For the in vitro neutralization test,
100 ml of pre-immune serum, anti-rLiD1 serum or commercial
Peruvian anti-venom, produced at INS by hyperimmunization of
horses with L. laeta (Peru) venom, were incubated with 1 MND of
L. laeta (Peru), for 1 h, at 37 C and then injected intradermically in
rabbits. The animals were evaluated 24 h, 48 h and 72 h after the
challenge. The measurements of the dermonecrotic lesions were
determined as described by Furlanetto (1962). The diameters of
hemorrhagic and oedematogenic lesions were measured with a
scale meter and pachymeter, respectively. The venom incubated
with pre-immune serumwas capable of producing a dermonecrotic
lesion of 0.2 cm2, a hemorrhagic area of 8.05 cm2, and a 0.6 mm
thick edema. The commercial antivenom completely neutralized
the dermonecrotic and hemorrhagic activities of L. laeta (Peru) and
produced edema of 0.067 mm. Anti-rLiD1 serum was also capable
of completely neutralizing the dermonecrotic and hemorrhagic
activities of L. laeta (Peru) venom, but induced edema of 0.5 mm.
The oedematogenic activity of Loxosceles venoms has already
shown to be difﬁcult to neutralize (Mendes et al., 2013; Guimar~aes
et al., 2013). Other venom components may be responsible for
edema formation, as described by (Barbaro et al., 2010). However,
the pathophysiology of edema formation in loxoscelism is still
unknown.
To perform lethal neutralization assays, the median lethal dose
(LD50) of L. intermedia and L. laeta (Peru) venoms were established
in male CF1 mice (18e22 g). The animals were maintained in the
Centro de Bioterismo of the Centro Nacional de Produccion de
Biologicos of Instituto Nacional de Salud (INS), in Lima, Peru. The
experimental protocols followed the Guide for the Care and Use of
Laboratory Animals, (NIH Publication No. 85-23, revised 1996).
Groups of four mice were injected with different doses of each
venom, via intra-peritoneal (i.p.) route, dissolved in 0.5 ml of PBS-
BSA 0.1%. Forty-eight hours later, deaths were recorded and LD50
was calculated by Probit analysis (Finney, 1971).
Neutralization of venoms lethal activity by horse anti-rLiD1
antivenom or commercial antivenom were done by i.p. injection
of 2.5 LD50 of each crude venom, incubated previously (1 h, 37 C)
with 100 ml of either PBS, pre-immune serum, anti-rLiD1 serum orcommercial antivenom, as previously described (de Roodt et al.,
2002). Deaths were counted after 48 h of venom injection. The
neutralization tests, traditionally used for determination of
neutralizing potency of anti-loxoscelic antivenom in Peru
(Ministerio de Salúd, Peru, 2004), showed that the lethal activity of
L. intermedia was completely neutralized by horse sera raised
against rLiD1 and this serum achieved a 75% protection against
L. laeta (Peru) venom (Table 1). Protection against L. laeta (Peru)
venom may have not been complete because anti-rLiD1 serum is
directed against only one recombinant isoform of dermonecrotic
protein. Others isoforms within Loxosceles venoms may share
extensive similarity, but are not identical (Kalapothakis et al.,
2007). Some of L. laeta (Peru) isoforms could not have been
completely neutralized by anti-LiD1r antibodies which can be
responsible for the residual lethality observed. It is not excluded
either that other venom components, such as metalloproteases and
hyaluronidases, may also contribute to venom's lethality (Ferrer
et al., 2013).
These experiments show the crossed neutralization of Peruvian
L. laeta venom by anti-rLiD1 antibodies. The use of recombinant
proteins combined with crude venoms has proven to be capable of
generating antivenoms with satisfactory neutralization results us-
ing reduced amounts of crude venom (Figueiredo et al., 2014). The
present results provide the scientiﬁc basis to support the use of
rLiD1 in the production of Peruvian anti-loxoscelic antivenom. The
best protocol for immunization for production of anti-loxoscelic
antivenom using recombinant proteins is still under studies, but
seems to be a promising approach.Acknowledgments
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